IMPACT Trial: Intervention to iMProve AdherenCe Equitably

IMPACT Trial: Intervention to iMProve AdherenCe Equitably

To determine the efficacy of a multicomponent adherence intervention among participants with early-stage breast cancer on endocrine therapy and at least one oral cardiovascular disease (CVD) medication on adherence to endocrine therapy and to CVD medication at 24 weeks assessed by self-report using the Domains of Subjective Extent (DOSE)-Nonadherence questionnaire and also by pharmacy fill data assessed in the electronic health record (EHR).

Inclusion Criteria:

• Women or men age >18 years
• Diagnosed with stage I-III breast cancer prescribed endocrine therapy
• Within 3-years of the end of early active treatment (e.g., surgery, chemotherapy not including human epidermal growth factor receptor 2 (HER2)-directed therapy, radiation)
• Patients must be prescribed at least 1 antihypertensive or statin medication for CVD prevention
• Self-report of at least some nonadherence ET or CVD medication on DOSE-Nonadherence Extent of Nonadherence questionnaire

Exclusion Criteria:

• Evidence of breast cancer recurrence
• Non-English or Non-Spanish speaking
• Not cognitively able to complete study requirements
• Do not follow with either a primary care provider or cardiologist within the New York Presbyterian Health system's Epic EHR
• Inability to provide informed consent